STARD13 Human shRNA Plasmid Kit (Locus ID 90627)
CAT#: TL301354
STARD13 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 7740.00
Product images

CNY 4070.00
Specifications
Product Data | |
Product Name | STARD13 Human shRNA Plasmid Kit (Locus ID 90627) |
Locus ID | 90627 |
UniProt ID | Q9Y3M8 |
Synonyms | ARHGAP37; DLC2; GT650; LINC00464 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | STARD13 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 90627). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001243466, NM_001243474, NM_001243476, NM_052851, NM_178006, NM_178007, NM_178008, NM_178007.1, NM_178007.2, NM_052851.1, NM_052851.2, NM_178006.1, NM_178006.2, NM_178006.3, NM_001243474.1, NM_001243466.1, NM_001243476.1, NM_001243476.2, BC046563, NM_001243466.2, NM_052851.3, NM_178007.3, NM_001243476.3 |
Summary | This gene encodes a protein which contains an N-terminal sterile alpha motif (SAM) for protein-protein interactions, followed by an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a C-terminal STAR-related lipid transfer (START) domain. It may be involved in regulation of cytoskeletal reorganization, cell proliferation, and cell motility, and acts as a tumor suppressor in hepatoma cells. The gene is located in a region of chromosome 13 that is associated with loss of heterozygosity in hepatocellular carcinomas. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |
其它STARD13产品